The University of Oxford has launched a study to assess the safety and immune response of the Covid-19 vaccine it has developed with AstraZeneca Plc in children for the first time .The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17,according to an emailed statement from the university.AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Velit omnis animi et iure laudantium vitae, praesentium optio, sapiente distinctio illo?